Group 1 - The core viewpoint of the article highlights the strong financial performance of Lichen Industrial in Q3 2023, with significant year-on-year growth in revenue and net profit [1] - Lichen Industrial reported a revenue of approximately 3.48 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 35.09% [1] - The net profit attributable to shareholders of the listed company was approximately 101 million yuan, reflecting a year-on-year increase of 32.41% [1] - The basic earnings per share were reported at 0.772 yuan, which is a year-on-year increase of 33.1% [1] Group 2 - As of the report date, Lichen Industrial has a market capitalization of 2.9 billion yuan [2] - The article also discusses the broader context of the biopharmaceutical market in China, noting that this year, overseas licensing has generated sales of 80 billion US dollars [2] - There is a contrast drawn between the hot secondary market for biopharmaceuticals and the cooling fundraising environment in the primary market [2]
丽臣实业：2025年前三季度净利润约1.01亿元